ECSP077166A - Derivados de 3-(heteroaril-oxi)-2-alquil-1-aza-bicicloalquilo como ligandos alfa-7-nachr para el tratamiento de enfermedades del sistema nervioso central (cns) - Google Patents

Derivados de 3-(heteroaril-oxi)-2-alquil-1-aza-bicicloalquilo como ligandos alfa-7-nachr para el tratamiento de enfermedades del sistema nervioso central (cns)

Info

Publication number
ECSP077166A
ECSP077166A EC2007007166A ECSP077166A ECSP077166A EC SP077166 A ECSP077166 A EC SP077166A EC 2007007166 A EC2007007166 A EC 2007007166A EC SP077166 A ECSP077166 A EC SP077166A EC SP077166 A ECSP077166 A EC SP077166A
Authority
EC
Ecuador
Prior art keywords
nachr
aza
treatment
derivatives
bicicloalquilo
Prior art date
Application number
EC2007007166A
Other languages
English (en)
Inventor
Dominik Feuerbach
Konstanze Hurth
Bernard Lucien Roy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32893550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077166(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP077166A publication Critical patent/ECSP077166A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a derivados de 1-aza-bicicloalquilo de la fórmula (I), donde los sustituyentes son como se definen en la especificación, a procedimientos para su producción, su uso como farmacéuticos en la prevención y tratamiento de trastornos psicóticos y neurodegenerativos. Los compuestos reclamados actúan como ligandos de receptores de acetilcolina nicotínicos (NACHR).
EC2007007166A 2004-07-14 2007-01-12 Derivados de 3-(heteroaril-oxi)-2-alquil-1-aza-bicicloalquilo como ligandos alfa-7-nachr para el tratamiento de enfermedades del sistema nervioso central (cns) ECSP077166A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0415746.7A GB0415746D0 (en) 2004-07-14 2004-07-14 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP077166A true ECSP077166A (es) 2007-02-28

Family

ID=32893550

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007166A ECSP077166A (es) 2004-07-14 2007-01-12 Derivados de 3-(heteroaril-oxi)-2-alquil-1-aza-bicicloalquilo como ligandos alfa-7-nachr para el tratamiento de enfermedades del sistema nervioso central (cns)

Country Status (29)

Country Link
US (3) US20080194573A1 (es)
EP (2) EP1776360B1 (es)
JP (1) JP5122951B2 (es)
KR (1) KR101279201B1 (es)
CN (2) CN103554101B (es)
AT (1) ATE493407T1 (es)
AU (1) AU2005261866B8 (es)
BR (1) BRPI0513275A (es)
CA (1) CA2570155C (es)
CY (1) CY1111651T1 (es)
DE (1) DE602005025642D1 (es)
DK (1) DK1776360T3 (es)
EC (1) ECSP077166A (es)
EG (1) EG26020A (es)
ES (1) ES2357963T3 (es)
GB (1) GB0415746D0 (es)
HR (1) HRP20110206T1 (es)
IL (1) IL180309A (es)
MA (1) MA28693B1 (es)
MX (1) MX2007000504A (es)
NO (1) NO338622B1 (es)
NZ (1) NZ551800A (es)
PL (1) PL1776360T3 (es)
PT (1) PT1776360E (es)
RU (1) RU2402551C2 (es)
SI (1) SI1776360T1 (es)
TN (1) TNSN07007A1 (es)
WO (1) WO2006005608A1 (es)
ZA (1) ZA200610122B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AR049401A1 (es) * 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
DE602005025902D1 (de) 2004-10-15 2011-02-24 Neurosearch As Neue azabizyklische arylderivate und medizinische verwendung damit
GB0521508D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
EP1987032A1 (en) 2006-02-14 2008-11-05 NeuroSearch A/S 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
WO2009067579A1 (en) * 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
EP2959902A1 (en) * 2009-07-23 2015-12-30 Novartis AG Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
EP2525797A1 (en) * 2010-01-20 2012-11-28 Abbott Laboratories Methods for treating pain
PE20131394A1 (es) 2010-09-23 2014-01-11 Abbvie Inc Monohidrato de derivados de aza-adamantano
WO2012101060A1 (en) 2011-01-27 2012-08-02 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
AU2012232711B2 (en) 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
ES2776996T3 (es) 2011-10-20 2020-08-03 Novartis Ag Biomarcadores predictivos de la sensibilidad al tratamiento por el activador del receptor de la acetilcolina nicotínico alfa 7
CA2890018A1 (en) * 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Substituted indol-5-ol derivatives and their therapeutical applications
CN104837499B (zh) 2012-12-11 2018-02-23 诺华有限公司 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物
KR101879919B1 (ko) * 2013-01-15 2018-07-18 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
JP6338223B2 (ja) * 2013-01-15 2018-06-06 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
MX362819B (es) * 2013-01-15 2019-02-18 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.
US9758505B2 (en) 2014-02-12 2017-09-12 Iteos Therapeutics 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
EA201650031A1 (ru) 2014-05-15 2017-06-30 Итеос Терапьютик Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EP3623371A1 (en) * 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MX2017011951A (es) 2015-03-17 2018-06-15 Pfizer Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
JP6643814B2 (ja) 2015-05-14 2020-02-12 株式会社ジェイエスピー 架橋発泡粒子及び発泡粒子成形体
EP3334733A1 (en) 2015-08-10 2018-06-20 Pfizer Inc 3-indol substituted derivatives, pharmaceutical compositions and methods for use
JP6836866B2 (ja) 2016-09-16 2021-03-03 株式会社ジェイエスピー 架橋発泡粒子とその成形体
JP6519813B2 (ja) 2016-11-11 2019-05-29 株式会社ジェイエスピー 発泡粒子とその成形体
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP3920915A4 (en) 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB281309A (en) 1926-11-27 1928-03-29 Inventia Patent Verwert Ges Improvements in or relating to brushing machines having replaceable brush members
US3310553A (en) 1962-09-25 1967-03-21 Pfizer & Co C Alkylated thioxathenesulfonamides
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
DE2139107A1 (de) 1971-08-04 1973-02-15 Merck Patent Gmbh Heterocyclisch substituierte adenosinverbindungen
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3687980T2 (de) 1986-01-07 1993-06-17 Beecham Group Plc Indolderivate mit einer azabicyclischen seitenkette, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zusammensetzungen.
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
AU614513B2 (en) 1987-04-15 1991-09-05 Beecham Group Plc 1-azabicyclic compounds
CA1307790C (en) 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
GB8718445D0 (en) * 1987-08-04 1987-09-09 Wyeth John & Brother Ltd Pyridyl-ethers
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE8817121U1 (de) 1988-11-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Quinuclidine
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
CA2002182C (en) 1989-11-03 2000-06-13 Richard J. Wurtman Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use
YU84791A (sh) 1990-05-19 1994-06-10 Boehringer Ingelheim Kg. Biciklicni 1-aza-cikloalkalni
ZA913756B (en) * 1990-05-19 1993-01-27 Boehringer Ingelheim Int Bicyclic 1-aza-cycloalkanes
DE4116582A1 (de) 1990-05-19 1991-11-21 Boehringer Ingelheim Kg Bicyclische 1-aza-cycloalkane
KR930702312A (ko) 1990-08-31 1993-09-08 아만 히데아키 피리미딘 유도체 및 의약
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
AU1752792A (en) 1991-03-08 1992-10-06 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
GB9201749D0 (en) 1992-01-28 1992-03-11 Smithkline Beecham Plc Medicaments
JPH05310732A (ja) 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
AU3901393A (en) * 1992-04-10 1993-11-18 Zeneca Limited Biphenylylquinuclidine derivatives as squalene synthase inhibitors
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
AU7394394A (en) 1992-10-13 1995-12-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors
AU6010594A (en) 1993-02-12 1994-08-29 Sankyo Company Limited Isoxazoleoxy derivative
JPH06293768A (ja) 1993-02-12 1994-10-21 Sankyo Co Ltd イソオキサゾールオキシ誘導体
JP3235913B2 (ja) 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5512574A (en) 1994-12-21 1996-04-30 American Home Products Corporation Quinuclidine and azabicyclo 2.2.1! heptane pyrazinyl ethers as muscarinic agonists
JPH11512443A (ja) 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
FR2754261B1 (fr) 1996-10-08 1998-10-30 Synthelabo Derives de quinuclidine, leur preparation et leur application en therapeutique
WO1998054189A1 (en) 1997-05-30 1998-12-03 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
FR2772378B1 (fr) 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
ES2313900T3 (es) 1999-07-28 2009-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nicotina en angiogenesis y vasculogenesis terapeutica.
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
AU2001241056A1 (en) 2000-03-09 2001-09-17 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
GB0021885D0 (en) 2000-09-06 2000-10-18 Fujisawa Pharmaceutical Co New use
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
JP2005511574A (ja) 2001-10-26 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
DE10162375A1 (de) 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
WO2003072578A1 (en) * 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
WO2004016608A1 (en) 2002-08-14 2004-02-26 Neurosearch A/S Novel quinuclidine derivatives and their use
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
AU2003284898A1 (en) 2002-10-29 2004-05-25 Micro, Inc. Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
WO2004039815A2 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
AU2003280309A1 (en) 2002-11-11 2004-06-03 Neurosearch A/S 1,4-diazabicyclo (3,2,2)nonane derivatives, preparation and therapeutical use thereof
PL377777A1 (pl) * 2002-12-11 2006-02-20 Pharmacia & Upjohn Company Llc Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków
EP1587511A2 (en) 2003-01-22 2005-10-26 Pharmacia & Upjohn Company LLC Treatment of diseases with alpha-7 nach receptor full agonists
WO2005013910A2 (en) * 2003-08-07 2005-02-17 University Of South Florida Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors
JP4226981B2 (ja) 2003-09-24 2009-02-18 三井金属鉱業株式会社 プリント配線板の製造方法及びその製造方法で得られたプリント配線板
JP4824573B2 (ja) 2003-11-18 2011-11-30 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 腎不全、腎疾患または腎障害、特に糖尿病患者におけるこれらの治療のための医薬組成物
US7241773B2 (en) * 2003-12-22 2007-07-10 Abbott Laboratories 3-quinuclidinyl heteroatom bridged biaryl derivatives
WO2006065233A1 (en) 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137203A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
US20050137398A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
US20050137204A1 (en) * 2003-12-22 2005-06-23 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) * 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20070060588A1 (en) * 2003-12-22 2007-03-15 Jianguo Ji Fused bicycloheterocycle substituted quinuclidine derivatives
US7160876B2 (en) * 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
EP1718306A2 (en) 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
AU2005233642A1 (en) * 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyridines as potassium ion channel modulators
US7514450B2 (en) 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
AR049401A1 (es) * 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
DE602005025902D1 (de) 2004-10-15 2011-02-24 Neurosearch As Neue azabizyklische arylderivate und medizinische verwendung damit
GB0424564D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
EP1833480A2 (en) * 2004-11-30 2007-09-19 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
EP1866314B1 (en) * 2005-02-16 2010-09-15 NeuroSearch A/S Novel diazabicyclic aryl derivatives and their medical use
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
JP2008536932A (ja) * 2005-04-18 2008-09-11 サイード・アール・カーン チューブリン重合阻害剤：ボンゾイルフェニル尿素（ｂｐｕ）硫黄類似体の設計及び合成
FR2884822B1 (fr) * 2005-04-22 2007-06-29 Aventis Pharma Sa Derives de triazines, leur preparation et leur application en therapeutique
GB0508314D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
PE20070135A1 (es) * 2005-06-14 2007-03-09 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
GB0521508D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands

Also Published As

Publication number Publication date
CN103554101B (zh) 2016-05-11
JP2008506646A (ja) 2008-03-06
US20080194573A1 (en) 2008-08-14
MX2007000504A (es) 2007-03-08
GB0415746D0 (en) 2004-08-18
DK1776360T3 (da) 2011-03-14
HK1101285A1 (en) 2007-10-12
CN103554101A (zh) 2014-02-05
CN1984911A (zh) 2007-06-20
KR101279201B1 (ko) 2013-06-26
CA2570155C (en) 2013-02-12
WO2006005608A1 (en) 2006-01-19
IL180309A0 (en) 2007-06-03
PL1776360T3 (pl) 2011-05-31
DE602005025642D1 (de) 2011-02-10
HRP20110206T1 (hr) 2011-04-30
EP1776360B1 (en) 2010-12-29
EP1776360A1 (en) 2007-04-25
NZ551800A (en) 2010-11-26
EP2457911A1 (en) 2012-05-30
ZA200610122B (en) 2007-12-27
AU2005261866A1 (en) 2006-01-19
US9657010B2 (en) 2017-05-23
US8609662B2 (en) 2013-12-17
RU2007105350A (ru) 2008-08-20
CY1111651T1 (el) 2015-10-07
US20140057921A1 (en) 2014-02-27
BRPI0513275A (pt) 2008-05-06
RU2402551C2 (ru) 2010-10-27
NO20070714L (no) 2007-04-13
PT1776360E (pt) 2011-03-24
EG26020A (en) 2012-11-10
IL180309A (en) 2012-03-29
ES2357963T3 (es) 2011-05-04
KR20070032329A (ko) 2007-03-21
JP5122951B2 (ja) 2013-01-16
MA28693B1 (fr) 2007-06-01
AU2005261866B2 (en) 2009-12-10
TNSN07007A1 (en) 2008-06-02
CA2570155A1 (en) 2006-01-19
SI1776360T1 (sl) 2011-04-29
NO338622B1 (no) 2016-09-19
AU2005261866B8 (en) 2010-04-08
US20100093746A1 (en) 2010-04-15
ATE493407T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
ECSP077166A (es) Derivados de 3-(heteroaril-oxi)-2-alquil-1-aza-bicicloalquilo como ligandos alfa-7-nachr para el tratamiento de enfermedades del sistema nervioso central (cns)
PH12019500004A1 (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
TN2015000018A1 (en) 5-ht3 receptor antagonists
ATE534625T1 (de) Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
MX2010002900A (es) Derivados heterociclicos triciclicos.
WO2007065662A3 (en) Trisubstituted quinazolinone derivatives as vanilloid antagonists
GB0525069D0 (en) Organic compounds
EA200700707A1 (ru) Производные 2-ациламинотиазола
ATE443707T1 (de) Isoxazolin-indol-derivate mit verbesserter antipsychotischer und anxiolytischer aktivität
CR8390A (es) Derivados de morfolina como inhibidores de la reabsorcion de norepinefrina
BRPI0606730A2 (pt) derivados de fenil metanona 2,5-di-substituìdos como inibidores do transportador de glicina 1 (glyt-1) para o tratamento de distúbios neurológicos e neuropsiquiátricos
UY30134A1 (es) Derivados de biciclo (2.2.1)hept-7-ilamina
TN2010000432A1 (en) New compounds for the treatment of cns disorders
CL2008002660A1 (es) Compuestos derivados de quinolina sustituidos, inhibidores del receptor de serotonina 5-ht6; composicion farmaceutica; y su uso en el tratamiento de trastornos del sistema nervioso central, tales como alzheimer, esquizofrenia y obesidad.
UA107356C2 (en) Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders
PE20151069A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
TH80281A (th) อนุพันธ์ไพร์โรลิดิลตัวใหม่ของสารประกอบเฮทเทอโรอะโรมาติก
TH149042A (th) การเตรียมเตตระไฮโดรไพแรน สไปโร ไพโรลิดิโนนที่ถูกแทนที่ และพิเพอริดิโนน และการใช้ประโยชน์ในการรักษาของมัน